A new artificial intelligence-driven workflow, dubbed an autonomous AI co-scientist, has been developed to accelerate the discovery of next-generation inhibitors for the epidermal growth factor receptor (EGFR), specifically targeting the C797S mutation that confers resistance to osimertinib in non-small cell lung cancer (NSCLC).